Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
First Claim
1. A method of eliciting an analgesic effect in a subject in need thereof, comprising intrathecally administering to the subject a therapeutically effective amount of a cyclooxygenase 1 inhibitor or pharmaceutically acceptable salt thereof in a preservative-free pharmaceutically acceptable carrier.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention discloses a method of eliciting an analgesic effect in a subject in need thereof comprising intrathecally administering to the subject a therapeutically effective amount of a cyclooxygenase 1 inhibitor or pharmaceutically acceptable salt thereof in a preservative-free pharmaceutically acceptable carrier. The present invention further discloses pharmaceutical compositions comprising a cylcooxygenase 1 inhibitor or a pharmaceutically acceptable salt thereof and an adjuvant such as an adrenergic agonist, opioid analgesic, local anesthetic, and calcium channel blocker, and combinations thereof in a preservative-free pharmaceutically acceptable carrier. Kits comprising a composition comprising a cyclooxygenase 1 inhibitor or a pharmaceutically acceptable salt thereof in a preservative-free pharmaceutically acceptable carrier in a container suitable for delivery of the composition into an intrathecal administration device are also disclosed herein.
34 Citations
30 Claims
- 1. A method of eliciting an analgesic effect in a subject in need thereof, comprising intrathecally administering to the subject a therapeutically effective amount of a cyclooxygenase 1 inhibitor or pharmaceutically acceptable salt thereof in a preservative-free pharmaceutically acceptable carrier.
-
7. A method of eliciting an analgesic effect in a subject in need thereof, comprising intrathecally administering a therapeutically effective amount of ketorolac or a pharmaceutically acceptable salt thereof to the subject in a preservative-free pharmaceutically acceptable carrier.
-
8. A pharmaceutical composition comprising:
-
a cyclooxygenase 1 inhibitor or a pharmaceutically acceptable salt thereof, and an adjuvant selected from the group consisting of an adrenergic agonist, opioid analgesic, local anesthetic, and calcium channel blocker, and combinations thereof in a preservative-free pharmaceutically acceptable carrier. - View Dependent Claims (9, 10, 15, 16, 17)
-
-
11. A pharmaceutical composition comprising:
-
ketorolac or a pharmaceutically acceptable salt thereof, and an adjuvant selected from the group consisting of an adrenergic agonist, opioid analgesic, local anesthetic, and calcium channel blocker, and combinations thereof in a preservative-free pharmaceutically acceptable carrier. - View Dependent Claims (18)
-
- 12. A pharmaceutical composition comprising ketorolac or a pharmaceutically acceptable salt thereof and clonidine in a preservative-free pharmaceutically acceptable carrier.
- 13. A pharmaceutical composition comprising ketorolac or a pharmaceutically acceptable salt thereof and fentanyl in a preservative-free pharmaceutically acceptable carrier.
- 14. A pharmaceutical composition comprising ketorolac or a pharmaceutically acceptable salt thereof and lidocaine in a preservative-free pharmaceutically acceptable carrier.
- 22. A kit comprising a composition comprising a cyclooxygenase 1 inhibitor or a pharmaceutically acceptable salt thereof in a preservative-free pharmaceutically acceptable carrier in a container suitable for delivery of the composition into an intrathecal administration device.
-
30. A kit comprising a composition comprising ketorolac or a pharmaceutically acceptable salt thereof in a preservative-free pharmaceutically acceptable carrier in a container suitable for delivery of the composition into an intrathecal administration pump.
Specification